ViroLogic and AstraZeneca to Conduct Iressa Biomarker Study

ViroLogic has announced that it had entered into an agreement with AstraZeneca to conduct a cancer biomarker study with application to Iressa, AstraZeneca's selective epidermal growth factor receptor kinase inhibitor. ViroLogic, utilizing its proprietary eTag assays will test tumor samples from lung cancer patients treated with Iressa to evaluate the utility of these assays in targeting patients who would most likely benefit from Iressa.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19287320&full=1)